J&J beats estimates with 2nd-qtr results; pharma arm especially strong

19 July 2016
johnson-and-johnson-hq-big

US healthcare giant Johnson & Johnson (NYSE: JNJ) has announced sales of $18.5 billion for the second quarter of 2016, an increase of 3.9% compared to the second quarter of 2015.

Adjusted net earnings for the current quarter were $4.9 billion and adjusted diluted earnings per share (EPS) were $1.74, representing increases of 1.1% and 1.8%, respectively, compared to the same period in 2015.

Wall Street's estimates had predicted a lower $1.68 EPS on revenue of $17.97 billion, and the positive results led J&J’s share price to jump immediately by 1.35%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical